title: Postoperative survival According to the Glasgow Prognostic
  Score in Patients with Resected Lung Adenocarcinoma
abstract: Background: The Glasgow Prognostic Score (GPS) is calculated from measured CRP and albumin levels. We here
  evaluated the significance of the GPS in patients with resected pulmonary adenocarcinoma. Materials and Methods:
  The present study included 156 patients with lung adenocarcinoma who underwent lobectomy at Kanazawa Medical
  University between 2002 and 2012. Classification was into three groups: those with normal albumin (>=3.5 g/dl) and
  C-reactive protein (CRP) (<=1.0 mg/dl) levels were classified as GPS 0 (n =136), those with low albumin (<3.5 g/
  dl) or elevated CRP (>1.0 mg/dl) levels as GPS 1 (n = 16), and those with low albumin (<3.5 g/dl) and elevated CRP
  (>1.0 mg/dl) levels as GPS 2 (n = 4). We retrospectively investigated relationships between the patient characteristics
  including the GPS, and disease-free survival and cancer-specific survival. Results: The pathological stages of the
  patients were as follows: IA (n=78, 50%), IB (n=31, 19.9%), IIA (n=20.0, 12.8%), IIB (n=9.0, 5.7%), and IIIA (n=18.0,
  11.5%). Lobectomy was performed in all cases. The average GPS was 0.15 (0-2) and showed significant relationships
  with stage and tumor size. The 2-year survival rates in patients with GPS0, 1 and 2 were 81.4%, 38.4%, and 25.0%,
  respectively. Clear correlations were noted with both cancer-specific survival and disease-free survival. Furthermore,
  multivariate analysis revealed that GPS was a significant prognostic factor. Conclusions: The GPS could be a prognostic
  factor for patients with resected pulmonary adenocarcinoma.
authors.affiliation: Department of Thoracic Surgery, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan. Email: y-matti@kanazawa-med.ac.jp
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Machida
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Sagawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Tanaka
authors.forename: Nozomu
authors.initials: N
authors.lastname: Motono
authors.forename: Takuma
authors.initials: T
authors.lastname: Matsui
authors.forename: Katsuo
authors.initials: K
authors.lastname: Usuda
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
keywords: Lung adenocarcinoma; glasgow prognostic score; prognosis